WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards

SINGAPORE, Sept. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025 hosted by IMAPAC. Since 2017, WuXi Biologics has received multiple awards in various categories at IMAPAC's events.

APBCEA aims to celebrate the outstanding contributions of leading CDMO that are accelerating biologics innovation across Asia Pacific. This award recognizes excellence in biomanufacturing, cutting-edge R&D, technological innovation, and strategic partnerships that drive the development and commercialization of novel biologic therapies.

WuXi Biologics is committed to advancing integrated technology platforms to accelerate the discovery, development, and manufacturing of biologics. It boasts one of the industry's largest portfolios of complex biologics, with total integrated projects reaching 864, including 168 bispecific and multispecific antibodies and 225 ADCs. The development cycle for its monoclonal antibody projects, from DNA to Investigational New Drug (IND) application, has been shortened to 6 months, demonstrating high flexibility. Behind these milestone achievements lies the solid support of the company's world-class quality systems—which have achieved a 100% success rate in Pre-License Inspections (PLI) and passed 44 inspections by global regulatory authorities, including 22 conducted by the FDA and EMA. Leveraging these innovative technologies, world-class quality systems, an extensive global manufacturing network, and a proven track record of high success rates, WuXi Biologics provides end-to-end services for over 1000 clients worldwide, advancing their biologics into the clinic and on to the market.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned from both clients and the industry for the value we consistently deliver. Through unremitting efforts in pursuing excellence, adherence to world-class quality standards, a visionary leadership team, and the dedicated global team, we remain steadfast in empowering our partners to accelerate groundbreaking therapies to patients worldwide at an earlier date."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain. 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com 

Contacts

Business
[email protected]

Media
[email protected]

SOURCE WuXi Biologics